AMI Organics (ACUTAAS) Share Price Falls 2.13% Today; Price Action, Valuation and Peer Analysis
- September 11, 2026
- Posted by: Harsh Piplani
- Category: News
AMI Organics Share Price fell to Rs 3,377.8 on 11 September 2026, down Rs 73.45 or 2.13% for the day, taking the company’s market capitalisation to Rs 26,471.8 crore. The move has put this Healthcare stock from the Pharmaceuticals & Drugs industry in focus in today’s market update, especially because the decline comes with a still-elevated valuation profile and strong profitability ratios.
For readers tracking AMI Organics Share Price Today, the supplied data confirms the price fall but does not establish a company-specific catalyst behind today’s decline. That is why the stock is trending mainly on price action, not on a verified event in the data. At the same time, the key financial metrics remain notable: P/E at 73.16, P/B at 16.38, ROE at 24.08%, ROCE at 32.42%, EPS at 47.17, book value at 210.75 and dividend yield at 0.07. On Univest, investors would now watch whether the stock holds above key moving-average levels, how its valuation compares with the same-industry benchmark, and how it stacks up against larger listed pharmaceutical peers.
AMI Organics (ACUTAAS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,377.8 |
| Previous Close | Rs 3,451.25 |
| Today's Move | -Rs 73.45 (-2.13%) |
| Open | Rs 3,471.4 |
| High | Rs 3,485 |
| Low | Rs 3,365 |
| Turnover | Rs 6.76 crore |
| Market Capitalisation | Rs 26,471.8 crore |
| Market Cap Category | Large Cap |
AMI Organics Share Price Today reflects a clear intraday decline, with the stock falling from its previous close of Rs 3,451.25 to Rs 3,377.8. The trading session began at Rs 3,471.4, the stock touched a day high of Rs 3,485, and later slipped to a day low of Rs 3,365 before remaining near those weaker levels. Turnover stood at Rs 6.76 crore, showing that the counter drew measurable market attention during the session.
The shape of the day matters. Opening above the previous close and then moving lower through the session indicates that early strength did not sustain. The gap between the day high of Rs 3,485 and the current price of Rs 3,377.8 also shows that sellers had the upper hand after the opening phase. In absolute terms, the stock lost Rs 73.45 in a single session. As a Large Cap company by the supplied classification, AMI Organics Share Price is being watched not just for the decline itself but for what that move says about near-term sentiment. The next step is to place this price action beside the broader valuation and financial picture.
AMI Organics (ACUTAAS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 26,471.8 crore |
| P/E Ratio | 73.16x |
| P/B Ratio | 16.38x |
| ROE | 24.08% |
| ROCE | 32.42% |
| EPS | Rs 47.17 |
| Book Value Per Share | Rs 210.75 |
| Dividend Yield | 0.07% |
AMI Organics Fundamental Analysis shows a business that commands a premium valuation while also posting stronger-than-industry profitability metrics. The company’s market cap stands at Rs 26,471.8 crore, which places it above the same-industry market-cap median of Rs 750.93 crore and the industry average of Rs 14,206.91 crore. That size context is important, because market capitalisation reflects scale, not necessarily valuation comfort.
On valuation, the stock trades at a P/E ratio of 73.16 and a P/B ratio of 16.38. EPS is 47.17, which indicates the earnings attributable to each share, while book value per share is 210.75, showing the accounting net worth behind each share. Dividend yield is 0.07, a small historical payout relative to the current stock price. Profitability remains the stronger part of the AMI Organics Stock Analysis: ROE is 24.08% and ROCE is 32.42%, both healthy figures on their own. In simple terms, the supplied data shows a company that delivers robust return ratios, but one whose valuation multiples are already far above broad industry medians. That mix explains why today’s price fall is drawing attention on Univest and why valuation discipline remains central to the discussion.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 73.16x |
| Benchmark Median P/E | 32.73x |
| Benchmark Average P/E | 49.1x |
| Benchmark P/E Range | 3.4x to 701.57x |
| Company P/B Ratio | 16.38x |
| Benchmark Median P/B | 3.06x |
| Benchmark Average P/B | 4.42x |
| Company ROE | 24.08% |
| Benchmark Median ROE | 11.83% |
| Benchmark Average ROE | 11.22% |
| Company ROCE | 32.42% |
| Benchmark Median ROCE | 13.68% |
| Benchmark Average ROCE | 13.71% |
| Company Market Capitalisation | Rs 26,471.8 crore |
| Benchmark Median Market Cap | Rs 750.93 crore |
| Benchmark Average Market Cap | Rs 14,206.91 crore |
The Healthcare sector and Pharmaceuticals & Drugs industry backdrop shows why this stock attracts interest even on a down day. In the same-industry benchmark covering 200 companies, AMI Organics Share Price sits against a valuation range that is wide, but still meaningfully above the middle of the pack on most supplied measures. That gives useful context to today’s stock news.
The benchmark data shows the company’s P/E of 73.16 versus an industry median of 32.73 and average of 49.1, based on 169 companies. That means the stock trades above both the median and average same-industry earnings multiple, though still below the benchmark maximum of 701.57. Its P/B of 16.38 is also far above the industry median of 3.06 and average of 4.42, based on 199 companies, while remaining below the maximum of 27.2. On profitability, the picture is different. Company ROE of 24.08% is well above the industry median of 11.83% and average of 11.22. Company ROCE of 32.42% is also much higher than the industry median of 13.68% and average of 13.71, based on 199 companies. This makes the AMI Organics Share Price Fall noteworthy: the stock is priced at a premium, but that premium is supported by stronger return ratios than the broader industry benchmark.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,48,315.74 | 36.98 | 5.17 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,51,737.22 | 85.36 | 14.14 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,87,593.62 | 85.95 | 20.89 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,12,618.18 | 24.71 | 4.14 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,515.04 | 33.08 | 3.17 | 11.83 | 16 |
Peer comparison shows where AMI Organics stands within listed pharmaceutical names tracked in the supplied dataset. Relative to larger peers, the company combines a mid-range premium valuation with stronger profitability than several established names, though not all. This is a key part of AMI Organics Share Price analysis today.
Against Sun Pharmaceutical Industries, AMI Organics carries a much smaller market cap of Rs 26,471.8 crore versus Rs 4,48,315.74 crore, but its P/E of 73.16 is markedly higher than Sun’s 36.98, while its ROE of 24.08% and ROCE of 32.42% both exceed Sun’s 14.85% and 19.11%. Compared with Divi’s Laboratories, AMI Organics trades at a lower P/E than Divi’s 85.36, but a higher P/B than Divi’s 14.14, while also posting better ROE and ROCE than Divi’s 16.19% and 21.51%. Torrent Pharmaceuticals trades at a similar premium P/E of 85.95 and a higher P/B of 20.89, with stronger ROE at 26.76% but lower ROCE at 19.27%. Versus Zydus Lifesciences and Cipla, AMI Organics has substantially higher valuation multiples, but also better ROE and ROCE than both. In short, the stock sits in a premium valuation bracket, yet its profitability profile compares favourably with many peers in the same Healthcare industry.
Why Investors Are Watching AMI Organics
- The stock fell 2.13% today to Rs 3,377.8 after opening at Rs 3,471.4 and touching a low of Rs 3,365.
- Its current price remains above the 50-day moving average of Rs 3,226.34 and the 200-day moving average of Rs 2,757.44.
- Valuation is rich at 73.16 times earnings and 16.38 times book value, keeping AMI Organics Share Price in focus.
- Profitability metrics are strong, with ROE at 24.08% and ROCE at 32.42%, both above same-industry benchmark averages.
- The company operates in Pharmaceuticals & Drugs, where peer and sector comparisons highlight both premium pricing and stronger returns.
About AMI Organics
AMI Organics is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied company context, the stock is analysed alongside listed pharmaceutical peers such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. For investors following AMI Organics Stock News and company news, that industry placement matters because valuation and profitability are best judged relative to the same pharmaceutical benchmark set rather than in isolation.
Track AMI Organics Share Price on Univest
UseAMI Organics (ACUTAAS) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
On Univest, users can track AMI Organics Share Price live, review AMI Organics Share Price Update data, compare market capitalisation and valuation ratios, and monitor metrics such as P/E, P/B, ROE, ROCE, EPS, book value, dividend yield and 52-week levels when available. Univest also helps readers follow sector comparisons, peer positioning and broader market insights around AMI Organics Share Price Today and related stock updates.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did AMI Organics Share Price fall today?
Ans. The supplied data confirms that AMI Organics Share Price fell 2.13% to Rs 3,377.8 from the previous close of Rs 3,451.25. However, the data does not establish a company-specific catalyst for today’s decline.
What is AMI Organics Share Price Today?
Ans. AMI Organics Share Price Today is Rs 3,377.8. The stock is down Rs 73.45 for the session, after opening at Rs 3,471.4 and moving within an intraday range of Rs 3,365 to Rs 3,485.
What does today’s price action show for AMI Organics ?
Ans. Today’s price action shows that the stock opened above the previous close but weakened later in the session. It touched Rs 3,485 before slipping to Rs 3,365, indicating that early strength did not sustain.
How expensive is AMI Organics compared with its industry?
Ans. AMI Organics trades at a P/E of 73.16, higher than the same-industry median of 32.73 and average of 49.1. Its P/B of 16.38 is also above the industry median of 3.06 and average of 4.42.
What are the key fundamental metrics for AMI Organics ?
Ans. The key supplied metrics are market capitalisation of Rs 26,471.8 crore, P/E of 73.16, P/B of 16.38, ROE of 24.08%, ROCE of 32.42%, EPS of 47.17, book value of 210.75 and dividend yield of 0.07.
How does AMI Organics compare with pharmaceutical peers?
Ans. AMI Organics carries higher valuation multiples than peers such as Sun Pharma, Zydus Lifesciences and Cipla, but its ROE and ROCE are stronger than those companies in the supplied comparison set. Its market cap remains much smaller.
What sector does AMI Organics belong to?
Ans. AMI Organics belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The benchmark comparison in the supplied data covers 200 same-industry companies, which helps frame its valuation and profitability position.
What should investors monitor next in AMI Organics Share Price?
Ans. Investors can monitor whether the stock holds above Rs 3,226.34, its 50-day moving average, while tracking valuation against peers and industry benchmarks. The combination of premium multiples and strong profitability remains the central point to watch.
